A novel pre-clinical strategy to deliver antimicrobial doses of inhaled nitric oxide.

Effective treatment of respiratory infections continues to be a major challenge. In high doses (≥160 ppm), inhaled Nitric Oxide (iNO) has been shown to act as a broad-spectrum antimicrobial agent, including its efficacy in vitro for coronavirus family. However, the safety of prolonged in vivo implem...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Vinicius S Michaelsen, Rafaela V P Ribeiro, Edson Brambate, Aadil Ali, Aizhou Wang, Layla Pires, Mitsuaki Kawashima, Yu Zhang, Anajara Gazzalle, Shaf Keshavjee, Lorenzo Del Sorbo, Marcelo Cypel
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/be25913353d349a8a8fe74aa6e41fd90
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares